



Published in final edited form as:

Genesis. 2008 September ; 46(9): 499–505. doi:10.1002/dvg.20428.

Generation of *Cyp17iCre* transgenic mice and their application to conditionally delete estrogen receptor alpha (*Esr1*) from the ovary and testis

Phillip J. Bridges^{1,*}, Yongbum Koo^{2,*}, Dong-Wook Kang³, Susan Hudgins-Spivey¹, Zi-Jian Lan⁴, Xueping Xu⁴, Francesco DeMayo⁴, Austin Cooney⁴, and CheMyong Ko¹

¹ Division of Clinical and Reproductive Sciences, University of Kentucky, KY

² School of Biotechnology and Biomedical Sciences, Inje University, South Korea

³ Department of Pathology, Eulji University Hospital, South Korea

⁴ Department of Molecular and Cellular Biology, Baylor College of Medicine, TX

Abstract

A transgenic mouse line that expresses iCre under regulation of the Cytochrome P₄₅₀ 17 α -hydroxylase/17, 20-lyase (*Cyp17*) promoter was developed as a novel transgenic mouse model for the conditional deletion of genes specifically in the theca/interstitial cells of the ovary and Leydig cells of the testis. In this report we describe the development of *Cyp17iCre* mice and the application of these mice for conditional deletion of the estrogen receptor alpha (*Esr1*) gene in the theca/interstitial and Leydig cells of the female and male gonad, respectively. These mice will prove a powerful tool to inactivate genes in the gonad in a cell-specific manner.

Targeted gene deletion has become a powerful tool in the study of gene function with the utilization of this technology leading to marked progress in our understanding of both physiological and pathophysiological systems. The ovary is one organ where targeted genetic deletion has proven fruitful with the establishment of transgenic mice with Cre expression targeted to granulosa cells (Lécureuil *et al.*, 2002), somatic cells (Bingham *et al.*, 2006) and the oocyte (Lan *et al.*, 2004; Lewandoski *et al.*, 1997). However, our understanding of ovarian function cannot advance at optimal pace without a tool to specifically delete genes of interest from the other major endocrine cell population of the ovary, the theca/interstitial cells. Hence, our primary goal was to develop the mice necessary to allow the specific deletion of genes in the theca/interstitial cells of the ovary and in this report we describe the generation of such a line of transgenic mice, with codon-improved Cre (iCre) driven by the promoter to Cytochrome P₄₅₀ 17 α -hydroxylase/17, 20-lyase (*Cyp17*).

Cytochrome P₄₅₀ 17 α -hydroxylase/17, 20-lyase, the product of *Cyp17* gene expression, plays a major role in the control of sex steroid hormone synthesis by mediating the 17 α -hydroxylation of pregnenolone or progesterone to dehydroepiandrosterone or androstenedione, respectively. In the female mouse, *Cyp17* expression is primarily restricted to the ovary and placenta (Su *et al.*, 2002) and within the ovary, *Cyp17* is abundant in the gonadotropin-primed theca/interstitial cell population, but not the granulosa cells or oocyte (Zhang *et al.*, 2001), making it ideal for iCre targeting. Furthermore, coincident to the need of a transgenic mouse

Correspondence to: CheMyong Ko, Division of Clinical and Reproductive Sciences, University of Kentucky, KY 40536. E-mail: cko2@uky.edu.

*Phillip J. Bridges and Yongbum Koo contributed equally to this work.

line with iCre targeted to the theca/interstitial cells, is one also designed to allow the deletion of Leydig cell specific genes from the male gonad. Fortunately, the specificity of *Cyp17* expression to the Leydig cells of the testis (Zhang *et al.*, 2001) makes this line of mice also ideal as a tool to inactivate genes specifically within that endocrine population of cells. Hence, this report was widened as a functional characterization of these mice inclusive to both the sexes.

Three lines of *Cyp17iCre* founder mice were generated (A, B and C) by pronuclear injection of a KpnI/SalI DNA fragment derived from a *Cyp17iCre* expression plasmid (Figure 1). Then, to facilitate expression analysis, founder mice were crossed with the iCre reporter strain (Gt [ROSA]26Sor^{tm1Sor}; ROSA26) (Soriano, 1999). These mice have the *lacZ* reporter gene expressed when iCre excises a loxP-flanked polyadenylation sequence. Therefore, with iCre/loxP recombination, only tissues with functional iCre activity will express β -galactosidase which stains intensely blue to X-gal (Bell *et al.*, 2005). Analysis of X-gal staining in the ovaries and testis collected from each of the three lines of *Cyp17iCre*/ROSA26 mice revealed no dramatic differences in the pattern of staining, however extra-gonadal X-gal staining was observed in two of the three lines. In line B, mottled X-gal staining was observed in the lungs of adult mice and in line C, disperse X-gal staining was noted in embryos collected 16.5 days after conception. These two lines are described in only a limited fashion hereafter and were not evaluated for the functional analysis (generation of *Esr1*^{flox/flox}*Cyp17iCre* transgenic mice), described below.

In the *Cyp17iCre* (line A) female, gross analysis of the ovary, oviduct and uterus after staining of these tissues as an intact unit with X-gal revealed strong ovarian, weak oviductal and very sparse uterine expression of β -galactosidase (Figure 2). Further histological evaluation of gonadotropin-primed *Cyp17iCre*/ROSA26 ovaries revealed X-gal staining throughout the majority of the theca/interstitium with minor staining observed in some granulosa cells in the ovary (Figure 2). In the *Cyp17iCre*/ROSA26 testis, X-gal staining was observed specifically in the Leydig cells (Figure 2). Evaluation of fetal gonadal X-gal staining on embryonic day 16.5 revealed strong staining in the testis but not the ovary (Figure 2), consistent with the pattern of expression of mRNA for *Cyp17* in these tissues (Heikkila *et al.*, 2002).

Gross morphological analysis of the placenta and embryos collected from pregnant females on embryonic day 16.5 revealed the expected placental staining (Arensburg *et al.*, 1999; Durkee *et al.*, 1992) (Figure 3). Similar to the sexually dimorphic staining of X-gal to the embryonic gonads, distinct staining was observed in the male but not the female embryonic adrenal (Figure 3). However, some inconsistency is apparent in the reported expression levels of mRNA for *Cyp17* in the male versus female embryonic adrenal (Heikkila *et al.*, 2002; Keeney *et al.*, 1995). Within the pituitary gland, X-gal staining was apparent in the intermediate lobe whereas the anterior and posterior lobes remained free of expression (Figure 3), an unexpected finding that was consistent among the three original founder lines. Gross morphological analysis of the kidney, adrenal gland, spleen and whole brain revealed only occasional and very sparse staining. Minor mottled staining was observed in some areas of the lung, whereas the liver stained intensely blue (a consistent finding among the three transgenic lines). Whether the extra-gonadal expression of iCre to the liver translates to aberrant metabolic function is unlikely though as all transgenic mice maintained good health and developed at the expected rate of growth. Overall, X-gal staining indicated relatively specific incorporation of iCre.

To determine the functional ability of iCre to excise a floxed gene *in vivo*, *Cyp17iCre* mice was crossed with those having loxP sites flanking estrogen receptor alpha (*Esr1*) (Gieske *et al.*, 2008), with the goal of specifically deleting *Esr1* from the ovarian theca/interstitium and testicular Leydig cells. Because *Esr1* is localized to the theca/interstitial cells (Schomberg *et al.*, 1999) and the surface epithelium of the ovary (Urzua *et al.*, 2006), these mice were well

suites to test the ability to delete a gene specifically from our targeted population of cells. Furthermore, total genetic deletion of *Esr1* leads to the development of severe hemorrhagic ovarian cysts (Dupont *et al.*, 2000), making mice with a conditional deletion of this gene an excellent model for further analysis of the role of *Esr1* in ovarian health and reproductive function. Founder lines had also undergone multiple generations of breeding before crossing with *Esr1*^{flx/flx} mice, allowing analysis of functional excision via a transgene with a new stable insertion. Briefly, *Esr1*^{flx/flx} mice were created by a targeting strategy used to generate *Esr1*^{-/-} mice (Dupont *et al.*, 2000), as described previously (Gieske *et al.*, 2008). To generate *Esr1*^{flx/flx} *Cyp17iCre* mice, *Esr1*^{flx/flx} mice were first crossed with *Cyp17iCre* mice. *Esr1*^{flx/+} *Cyp17iCre* F1 heterozygotes were then bred with *Esr1*^{flx/flx} mice to generate four potential genotypes: *Esr1*^{flx/flx} *Cyp17iCre* (the desired transgenic), as well as *Esr1*^{flx/+} *Cyp17iCre*, *Esr1*^{flx/flx} and *Esr1*^{flx/+}. Analysis of *Esr1*^{flx/flx} *Cyp17iCre* mice indicated successful application of the *Cyp17iCre* line as a conditional deleter of *Esr1* within the gonad. Both in the ovary and testis of *Esr1*^{flx/flx} *Cyp17iCre* mice, deletion of *Esr1* was restricted to the gonads and abundant *Esr1* expression was maintained in the uterus, oviduct, and epididymis, respectively (Figure 4).

Within the ovary, normal *Cyp17* protein expression was observed by immunohistochemical analysis in the theca/interstitial cells of both *Esr1*^{flx/flx} and *Esr1*^{flx/flx} *Cyp17iCre* mice (Figure 5). In contrast, *Esr1* expression, while apparent in the theca/interstitial cells and ovarian surface epithelium of *Esr1*^{flx/flx} mice, was only detected in the ovarian surface epithelium of *Esr1*^{flx/flx} *Cyp17iCre* mice (Figure 5), indicating successful deletion of *Esr1* from the iCre-expressing theca/interstitium and maintained expression in the non-targeted ovarian surface epithelium. Similar results were observed in the testis. Normal *Cyp17* protein expression was observed in the Leydig cells of both *Esr1*^{flx/flx} and *Esr1*^{flx/flx} *Cyp17iCre* mice (Figure 5). *Esr1* expression was detected in the Leydig cells of *Esr1*^{flx/flx} mice but not in *Esr1*^{flx/flx} *Cyp17iCre* transgenic mice (Figure 5), again indicating successful deletion of *Esr1* from iCre-expressing cells after excision of the loxP sequence.

In summary, we report the development and application of a novel strain of transgenic mice with iCre targeted to the *Cyp17* promoter. The use of these mice to conditionally delete genes of interest from the theca/interstitial cells of the ovary and Leydig cells of the testis will allow rapid advancement of our understanding of gene function as it relates to fertility and reproductive health.

METHODS

Generation of *Cyp17iCre* Transgenic Mice

Three transgenic mouse lines were constructed that expressed iCre recombinase under the control of the mouse *Cyp17* promoter (*Cyp17iCre*). An iCre fragment was amplified from the iCre plasmid (pBlue.iCre, generously provided by Dr. R. Sprengel, Max-Planck Institute for Medical Research, Germany) by polymerase chain reaction (PCR), digested and subcloned into another plasmid (pGL3B-iCre) to generate a promoter-free iCre expression cassette (Shimshek *et al.*, 2002). Genomic DNA fragments corresponding to the promoter region of *Cyp17* were amplified from mouse (C57-B6) genomic DNA, and cloned into the promoter-free iCre expression cassette (pGL3B-iCre) to produce a *Cyp17iCre* expression plasmid (pGL3B-*Cyp17iCre*). The nucleotide sequences of this transgene vector, pGL3B-*Cyp17iCre*, were confirmed by sequence analysis. A KpnI/SalI DNA fragment from pGL3B-*Cyp17iCre* vector which contained the 3.34 kb *Cyp17* promoter, a 1.1 kb iCre coding sequence and a SV40 late poly A signal (Schorpp *et al.*, 1996) was cut, purified and microinjected into the pronuclei of fertilized eggs from C57-B6/SJL mice as previously described (Jorgez *et al.*, 2006; Lan *et al.*, 2004; Li *et al.*, 2005; Shimshek *et al.*, 2002). The microinjected eggs were transferred to

pseudopregnant mothers, yielding three viable *Cyp17iCre* founder mice that transferred this transgene to their progeny.

Animal use and Genotyping

Genomic DNA was extracted from ear punches or embryonic tails using the Easy DNA kit (Invitrogen), according to the manufacturer's directions. The presence of iCre or LacZ was determined by PCR using the following primer pairs: Cre-F (5'-tct gat gaa gtc agg aag aac c-3') and Cre-R (5'-gag atg tcc ttc act ctg att c-3'); LacZ-F (5'-gcg tta ccc aac tta atc g-3') and LacZ-R (5'-tgt gag cga gta aca acc-3') (Jorgez *et al.*, 2006). For the functional analysis, the primer sets ER α P2F (5'-gtg tca gaa aga gac aat-3') and ER α P3 (5'-ggc att acc act tct cct ggg agt ct-3') were used to determine the presence or absence of loxP sequences and the primer sets ER α P1 (5'-ttg ccc gat aac aat aac at-3') and ER α P3 were used to determine whether or not exon 3 had been deleted (Gieske *et al.*, 2008). Animal use was approved by the respective University of Kentucky and Baylor College of Medicine Animal Care and Use Committees.

Histochemical Analysis

X-gal staining for β -galactosidase expression was performed on fresh tissues collected at sacrifice with the reagents and protocol recommended for direct staining by the manufacturer (Specialty Media, NJ). Briefly, tissues were fixed with the supplied paraformaldehyde based-fixative for 1 h on ice, rinsed with two PBS-based rinse solutions at room temperature and then incubated overnight at 37°C in the dark with X-gal stock solution diluted 1:40 in the supplied base solution. After the overnight incubation, tissues were washed and embedded in either paraffin or OCT. Paraffin-embedded sections were cut to 7 μ m, deparaffinized by treatment with xylenes, rehydrated through a graded series of alcohols then rinsed and counterstained with nuclear fast red. Tissues embedded in OCT were cut to 10 μ m, rehydrated and counterstained with nuclear fast red.

Immunohistochemical analysis of *Esr1* and *Cyp17* was performed on ovaries and testis collected at sacrifice, fixed with 4% neutral buffered paraformaldehyde and then embedded in paraffin blocks. Sections were cut to 4 μ m and immunostaining performed on deparaffinized sections using an EnVision detection kit (DAKO, Carpinteria, CA), according to the manufacturer's instructions. Antigen-retrieval was performed using 10 mM citrate buffer (pH 6.0) in an autoclave for 15 min at 120°C and the endogenous peroxidase activity was blocked with 5% hydrogen peroxide for 15 min. Sections were then incubated with primary antibodies that recognized *Esr1* (mouse monoclonal 6F11, 1:40 dilution, Novocastra, Newcastle, UK), and *Cyp17* (rabbit polyclonal, 1:100 dilution, kindly provided by Dr. A.J. Conley, Department of Population Health and Reproduction, University of California-Davis (Pattison *et al.*, 2007)). 3,3'-diamino-benzidine (DAB, DAKO) or 3-amino-9-ethylcarbazole (AEC, DAKO) were then used as a chromogen and counterstaining was accomplished with Mayer's hematoxyline. Staining was examined using a BX51 microscope (Olympus, Japan) with images acquired using the DP-70 imaging system (Olympus).

ACKNOWLEDGMENTS

This work was supported by the University of Kentucky Start-Up Fund (C Ko), NIH grants (IR01HD052694, P20RR15592; C KO) and College of Health Sciences NR research Support Funds (C Ko). Dong Wook Kang is a recipient of a Korea Research Foundation Grant (KRF-2004-214-E00042, MOEHRD). The authors would like to thank Dr. A.J. Conley, Department of Population Health and Reproduction, University of California-Davis for kindly providing the *Cyp17* antisera and Dr. Myung Chan Gye, Scott Huffman and Sung Eun Lee (University of Kentucky) for technical assistance.

REFERENCES

- Arensburg J, Payne AH, Orly J. Expression of Steroidogenic Genes in Maternal and Extraembryonic Cells During Early Pregnancy in Mice. *Endocrinology* 1999;140:5220–5232. [PubMed: 10537152]
- Bell P, Limberis M, Gao G, Wu D, Bove MS, Sanmiguel JC, Wilson JM. An optimized protocol for detection of *E. coli* β -galactosidase in lung tissue following gene transfer. *Histochem Cell Biol* 2005;124:77–85. [PubMed: 15947941]
- Bingham NC, Verma-Kurvari S, Parada LF, Parker KL. Development of a steroidogenic factor 1/Cre transgenic mouse line. *Genesis* 2006;44:419–424. [PubMed: 16937416]
- Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors α (ER α) and β (ER β) on mouse reproductive phenotypes. *Development* 2000;127:4277–4291. [PubMed: 10976058]
- Durkee TJ, McLean MP, Hales DB, Payne AH, Waterman MR, Khan I, Gibori G. P450(17 α) and P450SCC gene expression and regulation in the rat placenta. *Endocrinology* 1992;130:1309–1317. [PubMed: 1537294]
- Gieske MC, Kim HJ, Legan SJ, Koo Y, Krust A, Chambon P, Ko C. Pituitary Gonadotroph Estrogen Receptor- α Is Necessary for Fertility in Females. *Endocrinology* 2008;149:20–27. [PubMed: 17947360]
- Heikkila M, Peltoketo H, Leppaluoto J, Ilves M, Vuolteenaho O, Vainio S. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. *Endocrinology* 2002;143:4358–4365. [PubMed: 12399432]
- Jorgez CJ, Mayo FJD, Matzuk MM. Inhibin α -iCre mice: Cre deleter lines for the gonads, pituitary, and adrenal. *Genesis* 2006;44:183–188. [PubMed: 16604527]
- Keeney DS, Jenkins CM, Waterman MR. Developmentally regulated expression of adrenal 17 α -hydroxylase cytochrome P450 in the mouse embryo. *Endocrinology* 1995;136:4872–4879. [PubMed: 7588219]
- Lan Z-J, Xu X, Cooney AJ. Differential Oocyte-Specific Expression of Cre Recombinase Activity in GDF-9-iCre, Zp3cre, and Msx2Cre Transgenic Mice. *Biol Reprod* 2004;71:1469–1474. [PubMed: 15215191]
- Lécureuil C, Fontaine I, Crepieux P, Guillou F. Sertoli and granulosa cell-specific Cre recombinase activity in transgenic mice. *Genesis* 2002;33:114–118. [PubMed: 12124943]
- Lewandoski M, Wassarman KM, Martin GR. Zp3-cre, a transgenic mouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line. *Current Biology* 1997;7:148–151. [PubMed: 9016703]
- Li S, Chen D, Sauvé Y, McCandless J, Chen Y, Chen C. Rhodopsin-iCre transgenic mouse line for Cre-mediated rod-specific gene targeting. *Genesis* 2005;41:73–80. [PubMed: 15682388]
- Pattison JC, Saltzman W, Abbott DH, Hogan BK, Nguyen AD, Husen B, Einspanier A, Conley AJ, Bird IM. Gender and gonadal status differences in zona reticularis expression in marmoset monkey adrenals: Cytochrome b5 localization with respect to cytochrome P450 17,20-lyase activity. *Molecular and Cellular Endocrinology* 2007;265-266:93–101. [PubMed: 17222503]
- Schomberg DW, Couse JF, Mukherjee A, Lubahn DB, Sar M, Mayo KE, Korach KS. Targeted Disruption of the Estrogen Receptor- α Gene in Female Mice: Characterization of Ovarian Responses and Phenotype in the Adult. *Endocrinology* 1999;140:2733–2744. [PubMed: 10342864]
- Shimshek DR, Kim J, Hübner MR, Spengel DJ, Buchholz F, Casanova E, Stewart AF, Seeburg PH, Sprengel R. Codon-improved Cre recombinase (iCre) expression in the mouse. *Genesis* 2002;32:19–26. [PubMed: 11835670]
- Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat Genet* 1999;21:70–71. [PubMed: 9916792]
- Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM, Schultz PG, Hogenesch JB. Large-scale analysis of the human and mouse transcriptomes. *PNAS* 2002;99:4465–4470. [PubMed: 11904358]
- Urzua U, Roby KF, Gangi LM, Cherry JM, Powell JI, Munroe DJ. Transcriptomic analysis of an in vitro murine model of ovarian carcinoma: functional similarity to the human disease and identification of prospective tumoral markers and targets. *J Cell Physiol* 2006;206:594–602. [PubMed: 16245302]

Zhang P, Compagnone NA, Fiore C, Vigne JL, Culp P, Musci TJ, Mellon SH. Developmental gonadal expression of the transcription factor SET and its target gene, P450c17 (17alpha-hydroxylase/c17,20 lyase). *DNA Cell Biol* 2001;20:613–624. [PubMed: 11749720]




Figure 1. Schematic representation of the *Cyp17*iCre transgene construct. A) Plasmid map of the completed *Cyp17*iCre construct. B) Linearized structure of Kpn I /Sal I fragment of the construct. This DNA fragment was used for oocyte injection.




Figure 2. β -galactosidase expression in gonadal tissues of *Cyp17iCre/ROSA26* mice. Upper panels: Direct X-gal staining of the adult female and male gonads. Sectioned images of the ovary and testis are shown. The sections were counterstaining with nuclear fast red. Lower panels: Direct X-gal staining of embryonic day 16.5 female and male gonads. Sectioned images of the ovary and testis are shown. The sections were counterstaining with nuclear fast red.




Figure 3. β -galactosidase expression in non-gonadal tissues of *Cyp17iCre/ROSA26* mice. Upper panels: Direct X-gal staining of the pituitary and placenta of a female mouse. Lower panels: Direct X-gal staining of the embryonic day 16.5 adrenal gland. Sectioned images of the male and female embryonic adrenal gland are shown. The sections were counterstaining with nuclear fast red.




Figure 4.

Gonad-specific deletion of *Esr1* gene by *Cyp17iCre* mice. Upper panels: Expression of *Esr1* in the reproductive tissues of a female *Esr1^{flox/flox} Cyp17iCre* mouse. Note strong *Esr1* expression both in oviduct and uterus but not in the ovary except for ovarian surface epithelial cells. Lower panels: Expression of *Esr1* in the reproductive tissues of a male *Esr1^{flox/flox} Cyp17iCre* mouse. Note strong *Esr1* expression in the efferent ductule and epididymis but not the testis.




Figure 5. Successful deletion of *Esr1* by the application of *Cyp17iCre* mice. **Upper panels:** Expression of *Cyp17* and *Esr1* in the ovary of *Esr1^{flox/flox}* and *Esr1^{flox/flox} Cyp17iCre* mice. Note that *Esr1* expression is absent in the theca/interstitial cells of the *Esr1^{flox/flox} Cyp17iCre* mouse ovary while *Cyp17* expression persists. **Lower panels:** Expression of *Cyp17* and *Esr1* in the testis of *Esr1^{flox/flox}* and *Esr1^{flox/flox} Cyp17iCre* mice. Note that *Esr1* expression is absent in the Leydig cells of the *Esr1^{flox/flox} Cyp17iCre* mouse testis while *Cyp17* expression persists.